Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Fulcrum Therapeutics, Inc. (FULC : NSDQ)

• Company Description    Fulcrum Therapeutics Inc. is a clinical-stage biopharmaceutical company. It is focused on genetically defined diseases with an initial focus on rare diseases. Fulcrum Therapeutics Inc. is based in Cambridge, United States. Number of Employees: 55

• Price / Volume Information    Yesterday's Closing Price: $6.57 Daily Weekly Monthly 20 Day Moving Average: 644,743 shares Shares Outstanding: 66.63 (millions) Market Capitalization: $437.78 (millions) Beta: 3.02 52 Week High: $15.74 52 Week Low: $5.88 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -18.69% -22.66% 12 Week -24.74% -30.43% Year To Date -41.91% -46.43%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 26 LANDSDOWNE STREET - CAMBRIDGE,MA 02139 USA ph: 617-651-8851 fax: - kgardner@lifesciadvisors.com http://www.fulcrumtx.com

• General Corporate Information    Officers Alex C. Sapir - Chief Executive Officer and President Kate Haviland - Chairman Alan Musso - Chief Financial Officer Greg Tourangeau - Vice President; Finance Sonja Banks - Director Peer Information Fulcrum Therapeutics, Inc. (CORR.) Fulcrum Therapeutics, Inc. (RSPI) Fulcrum Therapeutics, Inc. (CGXP) Fulcrum Therapeutics, Inc. (BGEN) Fulcrum Therapeutics, Inc. (GTBP) Fulcrum Therapeutics, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 359616109 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/26 Next Expected EPS Date: 08/04/26 Share - Related Items Shares Outstanding: 66.63 Most Recent Split Date: (:1) Beta: 3.02 Market Capitalization: $437.78 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.28 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-1.16 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 9.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/04/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 1.31 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 10.71% vs. Previous Quarter: 19.35% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 03/31/26 - -27.80 12/31/25 - -30.25 09/30/25 - -32.17 ROA 03/31/26 - -26.32 12/31/25 - -28.45 09/30/25 - -30.04 Current Ratio 03/31/26 - 34.33 12/31/25 - 27.40 09/30/25 - 17.70 Quick Ratio 03/31/26 - 34.33 12/31/25 - 27.40 09/30/25 - 17.70 Operating Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Net Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Pre-Tax Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Book Value 03/31/26 - 5.00 12/31/25 - 6.45 09/30/25 - 3.67 Inventory Turnover 03/31/26 - - 12/31/25 - - 09/30/25 - - Debt-to-Equity 03/31/26 - 0.00 12/31/25 - 0.00 09/30/25 - 0.00 Debt-to-Capital 03/31/26 - 0.00 12/31/25 - 0.00 09/30/25 - 0.00

Powered by Zacks Investment Research ©